N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators

Journal of Medicinal Chemistry

Volumn 59, Issue 1, 2016, Pages 61-81

  Blöcher, René ^a   Lamers, Christina ^a   Wittmann, Sandra K ^a   Merk, Daniel ^a   Hartmann, Markus ^a   Weizel, Lilia ^a   Diehl, Olaf ^a   Brüggerhoff, Astrid ^a   Boß, Marcel ^a   Kaiser, Astrid ^a   Schader, Tim ^a   Göbel, Tamara ^a   Grundmann, Manuel ^b   Angioni, Carlo ^a   Heering, Jan ^c   Geisslinger, Gerd ^a   Wurglics, Mario ^a   Kostenis, Evi ^b   Brüne, Bernhard ^a   Steinhilber, Dieter ^a   Schubert Zsilavecz, Manfred ^a   Kahnt, Astrid S ^a   Proschak, Ewgenij ^a   more..

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 3 [4 (N BENZYLBENZAMIDE)]PROPIONIC ACID; 2 ETHYL 3 [4 [ N [(2 TRIFLUOROMETHYL)BENZYL]BENZAMIDE]]PROPANOATE; 2 ETHYL 3 [4 [ N [(2 TRIUOROMETHYL)BENZYL]BENZAMIDE]]PROPIONIC ACID; 2 ETHYL 3 [4 [ N [(4 PHENOXY)BENZYL]BENZAMIDE]]PROPIONIC ACID; 2 ETHYL 3 [4 [ N [4 METHOXY(2 TRIFLUOROMETHYL)BENZYL]BENZAMIDE]]PROPIONIC ACID; 2 ETHYL 3 [4 [N [(2 CHLORO)BENZYL]BENZAMIDE]]PROPIONIC ACID; 2 ETHYL 3 [4 [N [(2 METHYL)BENZYL]BENZAMIDE]]PROPIONIC ACID; 2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; 4 [N BENZYLBENZAMIDE] ALPHA ETHYLCINNAMIC ACID; 4 [N [(2 CHLORO)BENZYL]BENZAMIDE] ALPHA ETHYLCINNAMIC ACID; 4 [N [(2 METHYL)BENZYL]BENZAMIDE] ALPHA ETHYLCINNAMIC ACID; 4 [N [(2 TRIFLUOROMETHYL)BENZYL]BENZAMIDE] ALPHA ETHYLCINNAMIC ACID; ANTIMETABOLITE; BENZAMIDE DERIVATIVE; EPOXIDE HYDROLASE; ETHYL 2 ETHYL 3 [4 (N BENZYLBENZAMIDE)]PROPANOATE; ETHYL 2 ETHYL 3 [4 [N [( BROMO)BENZYL]BENZAMIDE]]PROPANOATE; ETHYL 2 ETHYL 3 [4 [N [(2 CHLORO)BENZYL]BENZAMIDE]]PROPANOATE; ETHYL 2 ETHYL 3 [4 [N [(2 METHYL)BENZYL]BENZAMIDE]]PROPANOATE; ETHYL 4 [N BENZYLBENZAMIDE] ALPHA ETHYLCINNAMATE; ETHYL 4 [N [(2 BROMO)BENZYL]BENZAMIDE] ALPHA ETHYLCINNAMATE; ETHYL 4 [N [(2 CHLORO)BENZYL]BENZAMIDE] ALPHA ETHYLCINNAMATE; ETHYL 4 [N [(2 METHYL)BENZYL]BENZAMIDE] ALPHA ETHYLCINNAMATE; ETHYL 4 [N [[2 (TRIFLUOROMETHYL) BENZYL]BENZAMIDE] ALPHA ETHYLCINNAMATE; N BENZYLBENZAMIDE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ENZYME INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SCREENING; DRUG SYNTHESIS; EC50; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; METABOLIC SYNDROME X; MOUSE; NONHUMAN; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; 3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; HYPERTENSION; LIVER MICROSOME; METABOLISM; ORAL DRUG ADMINISTRATION; RAT; SYNTHESIS;

3T3 CELLS; ADMINISTRATION, ORAL; ANIMALS; BENZAMIDES; CERCOPITHECUS AETHIOPS; COS CELLS; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HUMANS; HYPERTENSION; IN VITRO TECHNIQUES; METABOLIC SYNDROME X; MICE; MICROSOMES, LIVER; PPAR GAMMA; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84955121284     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01239     Document Type: Article

References (50)

1. Eckel, R. H.; Alberti, K.; Grundy, S. M.; Zimmet, P. Z. The Metabolic Syndrome Lancet 2010, 375, 181-183 10.1016/S0140-6736(09)61794-3
2. Javed, S.; Petropoulos, I. N.; Alam, U.; Malik, R. A. Treatment of Painful Diabetic Neuropathy Ther. Adv. Chronic Dis. 2015, 6, 15-28 10.1177/2040622314552071
3. Chan, G. C. W.; Tang, S. C. W. Diabetic Nephropathy: Landmark Clinical Trials and Tribulations Nephrol., Dial., Transplant. 2015, 1-10 10.1093/ndt/gfu411
4. Grundy, S. M. Drug Therapy of the Metabolic Syndrome: Minimizing the Emerging Crisis in Polypharmacy Nat. Rev. Drug Discovery 2006, 5, 295-309 10.1038/nrd2005
5. Grundy, S. M.; Cleeman, J. I.; Daniels, S. R.; Donato, K. A.; Eckel, R. H.; Franklin, B. A.; Gordon, D. J.; Krauss, R. M.; Savage, P. J.; Smith, S. C.; Spertus, J. A.; Costa, F. Diagnosis and Management of the Metabolic Syndrome Circulation 2005, 112, 2735-2752 10.1161/CIRCULATIONAHA.105.169404
6. Morphy, R.; Rankovic, Z. Designed Multiple Ligands. An Emerging Drug Discovery Paradigm J. Med. Chem. 2005, 48, 6523-6543 10.1021/jm058225d
7. Tontonoz, P.; Spiegelman, B. M. Fat and beyond: The Diverse Biology of PPAR Gamma Annu. Rev. Biochem. 2008, 77, 289-312 10.1146/annurev.biochem.77.061307.091829
8. Staels, B.; Fruchart, J.-C. Therapeutic Roles of Peroxisome Proliferator-activated Receptor Agonists Diabetes 2005, 54, 2460 10.2337/diabetes.54.8.2460
9. Ahmadian, M.; Suh, J. M.; Hah, N.; Liddle, C.; Atkins, A. R.; Downes, M.; Evans, R. M. PPARγ Signaling and Metabolism: The Good, the Bad and the Future Nat. Med. 2013, 99, 557-566 10.1038/nm.3159
10. Rohatgi, A.; McGuire, D. K. Effects of the Thiazolidinedione Medications on Micro- and Macrovascular Complications in Patients with Diabetes-Update 2008 Cardiovasc. Drugs Ther. 2008, 22, 233-240 10.1007/s10557-008-6093-z
11. Cariou, B.; Charbonnel, B.; Staels, B. Thiazolidinediones and PPARγ Agonists: Time for a Reassessment Trends Endocrinol. Metab. 2012, 23, 205-215 10.1016/j.tem.2012.03.001
12. Taeye, B. M. De; Morisseau, C.; Coyle, J.; Covington, J. W.; Yang, J.; Murphy, S. B.; Friedman, D. B.; Hammock, B. B.; Vaughan, E. Expression and Regulation of Soluble Epoxide Hydrolase in Adipose Tissue Obesity 2010, 18, 489-498 10.1038/oby.2009.227
13. Imig, J. D.; Hammock, B. D. Soluble Epoxide Hydrolase as a Therapeutic Target for Cardiovascular Diseases Nat. Rev. Drug Discovery 2009, 8, 794-805 10.1038/nrd2875
14. Huang, A.; Sun, D.; Jacobson, A.; Carroll, M. a.; Falck, J. R.; Kaley, G. Epoxyeicosatrienoic Acids Are Released to Mediate Shear Stress-Dependent Hyperpolarization of Arteriolar Smooth Muscle Circ. Res. 2005, 96, 376-383 10.1161/01.RES.0000155332.17783.26
15. Fleming, I. The Pharmacology of the Cytochrome P450 Epoxygenase/soluble Epoxide Hydrolase Axis in the Vasculature and Cardiovascular Disease Pharmacol. Rev. 2014, 66, 1106-1140 10.1124/pr.113.007781
16. Liu, Y.; Zhang, Y.; Schmelzer, K.; Lee, T.-S.; Fang, X.; Zhu, Y.; Spector, A. A.; Gill, S.; Morisseau, C.; Hammock, B. D.; Shyy, J. Y.-J. The Antiinflammatory Effect of Laminar Flow: The Role of PPARgamma, Epoxyeicosatrienoic Acids, and Soluble Epoxide Hydrolase Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 16747-16752 10.1073/pnas.0508081102
17. Xu, D. Y.; Davis, B. B.; Wang, Z. H.; Zhao, S. P.; Wasti, B.; Liu, Z. L.; Li, N.; Morisseau, C.; Chiamvimonvat, N.; Hammock, B. D. A Potent Soluble Epoxide Hydrolase Inhibitor, T-AUCB, Acts through PPARγ to Modulate the Function of Endothelial Progenitor Cells from Patients with Acute Myocardial Infarction Int. J. Cardiol. 2013, 167, 1298-1304 10.1016/j.ijcard.2012.03.167
18. Luo, P.; Chang, H.-H.; Zhou, Y.; Zhang, S.; Hwang, S. H.; Morisseau, C.; Wang, C.-Y.; Inscho, E. W.; Hammock, B. D.; Wang, M.-H. Inhibition or Deletion of Soluble Epoxide Hydrolase Prevents Hyperglycemia, Promotes Insulin Secretion, and Reduces Islet Apoptosis J. Pharmacol. Exp. Ther. 2010, 334, 430-438 10.1124/jpet.110.167544
19. Capdevila, J. H.; Falck, J. R.; Imig, J. D. Roles of the Cytochrome P450 Arachidonic Acid Monooxygenases in the Control of Systemic Blood Pressure and Experimental Hypertension Kidney Int. 2007, 72, 683-689 10.1038/sj.ki.5002394
20. Imig, J. D.; Walsh, K. a; Hye Khan, M. A.; Nagasawa, T.; Cherian-Shaw, M.; Shaw, S. M.; Hammock, B. D. Soluble Epoxide Hydrolase Inhibition and Peroxisome Proliferator Activated Receptor γ Agonist Improve Vascular Function and Decrease Renal Injury in Hypertensive Obese Rats Exp. Biol. Med. 2012, 237, 1402-1412 10.1258/ebm.2012.012225
21. Buscató, E.; Blöcher, R.; Lamers, C.; Klingler, F.-M.; Hahn, S.; Steinhilber, D.; Schubert-Zsilavecz, M.; Proschak, E. Design and Synthesis of Dual Modulators of Soluble Epoxide Hydrolase and Peroxisome Proliferator-Activated Receptors J. Med. Chem. 2012, 55, 10771-10775 10.1021/jm301194c
22. Sime, M.; Allan, A. C.; Chapman, P.; Fieldhouse, C.; Giblin, G. M. P.; Healy, M. P.; Lambert, M. H.; Leesnitzer, L. M.; Lewis, A.; Merrihew, R. V.; Rutter, R. a.; Sasse, R.; Shearer, B. G.; Wilson, T. M.; Xu, R. X.; Virley, D. J. Discovery of GSK1997132B a Novel Centrally Penetrant Benzimidazole PPARγ Partial Agonist Bioorg. Med. Chem. Lett. 2011, 21, 5568-5572 10.1016/j.bmcl.2011.06.088
23. Thalji, R. K.; McAtee, J. J.; Belyanskaya, S.; Brandt, M.; Brown, G. D.; Costell, M. H.; Ding, Y.; Dodson, J. W.; Eisennagel, S. H.; Fries, R. E.; Gross, J. W.; Harpel, M. R.; Holt, D. a.; Israel, D. I.; Jolivette, L. J.; Krosky, D.; Li, H.; Lu, Q.; Mandichak, T.; Roethke, T.; Schnackenberg, C. G.; Schwartz, B.; Shewchuk, L. M.; Xie, W.; Behm, D. J.; Douglas, S. a.; Shaw, A. L.; Marino, J. P. Discovery of 1-(1,3,5-Triazin-2-Yl)piperidine-4-Carboxamides as Inhibitors of Soluble Epoxide Hydrolase Bioorg. Med. Chem. Lett. 2013, 23, 3584-3588 10.1016/j.bmcl.2013.04.019
24. Nomura, M.; Tanase, T.; Ide, T.; Tsunoda, M.; Suzuki, M.; Uchiki, H.; Murakami, K.; Miyachi, H. Design, Synthesis, and Evaluation of Substituted Phenylpropanoic Acid Derivatives as Human Peroxisome Proliferator Activated Receptor Activators. Discovery of Potent and Human Peroxisome Proliferator Activated Receptor Alpha Subtype-Selective Activators J. Med. Chem. 2003, 46, 3581-3599 10.1021/jm0205144
25. Ohashi, M.; Nakagome, I.; Kasuga, J. I.; Nobusada, H.; Matsuno, K.; Makishima, M.; Hirono, S.; Hashimoto, Y.; Miyachi, H. Design, Synthesis and in Vitro Evaluation of a Series of Alpha-Substituted Phenylpropanoic Acid PPARgamma Agonists to Further Investigate the Stereochemistry-Activity Relationship Bioorg. Med. Chem. 2012, 20, 6375-6383 10.1016/j.bmc.2012.08.061
26. Schmitt, M. L.; Hauser, A. T.; Carlino, L.; Pippel, M.; Schulz-Fincke, J.; Metzger, E.; Willmann, D.; Yiu, T.; Barton, M.; Schüle, R.; Sippl, W.; Jung, M. Nonpeptidic Propargylamines as Inhibitors of Lysine Specific Demethylase 1 (LSD1) with Cellular Activity J. Med. Chem. 2013, 56, 7334-7342 10.1021/jm400792m
27. Hieke, M.; Ness, J.; Steri, R.; Greiner, C.; Werz, O.; Schubert-Zsilavecz, M.; Weggen, S.; Zettl, H. SAR Studies of Acidic Dual Gamma-secretase/PPARgamma Modulators Bioorg. Med. Chem. 2011, 19, 5372-5382 10.1016/j.bmc.2011.08.003
28. Proschak, E.; Sander, K.; Zettl, H.; Tanrikulu, Y.; Rau, O.; Schneider, P.; Schubert-Zsilavecz, M.; Stark, H.; Schneider, G. From Molecular Shape to Potent Bioactive Agents II: Fragment-Based de Novo Design ChemMedChem 2009, 4, 45-48 10.1002/cmdc.200800314
29. Giannetti, A. M.; Zheng, X.; Skelton, N. J.; Wang, W.; Bravo, B. J.; Bair, K. W.; Baumeister, T.; Cheng, E.; Crocker, L.; Feng, Y.; Gunzner-Toste, J.; Ho, Y.-C.; Hua, R.; Liederer, B. M.; Liu, Y.; Ma, X.; OBrien, T.; Oeh, J.; Sampath, D.; Shen, Y.; Wang, C.; Wang, L.; Wu, H.; Xiao, Y.; Yuen, P.; Zak, M.; Zhao, G.; Zhao, Q.; Dragovich, P. S. Fragment-Based Identification of Amides Derived from Trans-2-(Pyridin-3-Yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT) J. Med. Chem. 2014, 57, 770-792 10.1021/jm4015108
30. Reichelt, A.; Gaul, C.; Frey, R. R.; Kennedy, A.; Martin, S. F. Design, Synthesis, and Evaluation of Matrix Metalloprotease Inhibitors Bearing Cyclopropane-Derived Peptidomimetics as P1′ and P2′ Replacements J. Org. Chem. 2002, 67, 4062-4075 10.1021/jo0110698
31. Morini, G.; Comini, M.; Rivara, M.; Rivara, S.; Bordi, F.; Plazzi, P. V.; Flammini, L.; Saccani, F.; Bertoni, S.; Ballabeni, V.; Barocelli, E.; Mor, M. Synthesis and Structure-Activity Relationships for Biphenyl H3 Receptor Antagonists with Moderate Anti-Cholinesterase Activity Bioorg. Med. Chem. 2008, 16, 9911-9924 10.1016/j.bmc.2008.10.029
32. Zhao, H. The Synthesis and Structures of Deuterium-Labeled 5-Substituted 1 H -Tetrazoles J. Labelled Compd. Radiopharm. 2008, 51, 293-296 10.1002/jlcr.1524
33. Xing, L.; McDonald, J. J.; Kolodziej, S. a; Kurumbail, R. G.; Williams, J. M.; Warren, C. J.; ONeal, J. M.; Skepner, J. E.; Roberds, S. L. Discovery of Potent Inhibitors of Soluble Epoxide Hydrolase by Combinatorial Library Design and Structure-Based Virtual Screening J. Med. Chem. 2011, 54, 1211-1222 10.1021/jm101382t
34. Ishiyama, M.; Tominaga, H.; Shiga, M.; Sasamoto, K.; Ohkura, Y.; Ueno, K. A Combined Assay of Cell Viability and in Vitro Cytotoxicity with a Highly Water-Soluble Tetrazolium Salt, Neutral Red and Crystal Violet Biol. Pharm. Bull. 1996, 19, 1518-1520 10.1248/bpb.19.1518
35. Morisseau, C.; Goodrow, M. H.; Newman, J. W.; Wheelock, C. E.; Dowdy, D. L.; Hammock, B. D. Structural Refinement of Inhibitors of Urea-Based Soluble Epoxide Hydrolases Biochem. Pharmacol. 2002, 63, 1599-1608 10.1016/S0006-2952(02)00952-8
36. Shen, L.; Peng, H.; Zhao, S.; Xu, D. A Potent Soluble Epoxide Hydrolase Inhibitor, T-AUCB, Modulates Cholesterol Balance and Oxidized Low Density Lipoprotein Metabolism in Adipocytes in Vitro Biol. Chem. 2014, 395, 443-451 10.1515/hsz-2013-0251
37. Gomez, G. A.; Morisseau, C.; Hammock, B. D.; Christianson, D. W. Structure of Human Epoxide Hydrolase Reveals Mechanistic Inferences on Bifunctional Catalysis in Epoxide and Phosphate Ester Hydrolysis Biochemistry 2004, 43, 4716-4723 10.1021/bi036189j
38. Guan, Y.; Breyer, M. D. Peroxisome Proliferator-Activated Receptors (PPARs): Novel Therapeutic Targets in Renal Disease Kidney Int. 2001, 60, 14-30 10.1046/j.1523-1755.2001.00766.x
39. Lu, M.; Sarruf, D. A.; Talukdar, S.; Sharma, S.; Li, P.; Bandyopadhyay, G.; Nalbandian, S.; Fan, W.; Gayen, J. R.; Mahata, S. K.; Webster, N. J.; Schwartz, M. W.; Olefsky, J. M. Brain PPARγ Promotes Obesity and Is Required for the Insulin- Sensitizing Effect of Thiazolidinediones Nat. Med. 2011, 17, 618-622 10.1038/nm.2332
40. Lamers, C.; Schubert-Zsilavecz, M.; Merk, D. Therapeutic Modulators of Peroxisome Proliferator-Activated Receptors (PPAR): A Patent Review (2008-Present) Expert Opin. Ther. Pat. 2012, 22, 803-841 10.1517/13543776.2012.699042
41. Niesen, F. H.; Berglund, H.; Vedadi, M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability Nat. Protoc. 2007, 2, 2212-21 10.1038/nprot.2007.321
42. Huang, S. X.; Li, H. Y.; Liu, J. Y.; Morisseau, C.; Hammock, B. D.; Long, Y. Q. Incorporation of Piperazino Functionality into 1,3-Disubstituted Urea as the Tertiary Pharmacophore Affording Potent Inhibitors of Soluble Epoxide Hydrolase with Improved Pharmacokinetic Properties J. Med. Chem. 2010, 53, 8376-8386 10.1021/jm101087u
43. Peters, J. U. Polypharmacology-Foe or Friend? J. Med. Chem. 2013, 56, 8955-8971 10.1021/jm400856t
44. Yang, T.; Soodvilai, S. Renal and Vascular Mechanisms of Thiazolidinedione-Induced Fluid Retention PPAR Res. 2008, 2008, 943614 10.1155/2008/943614
45. Wolf, N. M.; Morisseau, C.; Jones, P. D.; Hock, B.; Hammock, B. D. Development of a High-Throughput Screen for Soluble Epoxide Hydrolase Inhibition Anal. Biochem. 2006, 355, 71-80 10.1016/j.ab.2006.04.045
46. Rau, O.; Wurglics, M.; Paulke, A.; Zitzkowski, J.; Meindl, N.; Bock, A.; Dingermann, T.; Abdel-Tawab, M.; Schubert-Zsilavecz, M. Carnosic Acid and Carnosol, Phenolic Diterpene Compounds of the Labiate Herbs Rosemary and Sage, Are Activators of the Human Peroxisome Proliferator-Activated Receptor Gamma Planta Med. 2006, 72, 881-887 10.1055/s-2006-946680
47. Brown, P. J.; Stuart, L. W.; Hurley, K. P.; Lewis, M. C.; Winegar, D. A.; Wilson, J. G.; Wilkison, W. O.; Ittoop, O. R.; Willson, T. M. Identification of a Subtype Selective Human PPARalpha Agonist through Parallel-Array Synthesis Bioorg. Med. Chem. Lett. 2001, 11, 1225-1227 10.1016/S0960-894X(01)00188-3
48. Berger, J.; Leibowitz, M. D.; Doebber, T. W.; Elbrecht, A.; Zhang, B.; Zhou, G.; Biswas, C.; Cullinan, C. A.; Hayes, N. S.; Li, Y.; Tanen, M.; Ventre, J.; Wu, M. S.; Berger, G. D.; Mosley, R.; Marquis, R.; Santini, C.; Sahoo, S. P.; Tolman, R. L.; Smith, R. G.; Moller, D. E. Novel Peroxisome Proliferator-Activated Receptor (PPAR) Gamma and PPARdelta Ligands Produce Distinct Biological Effects J. Biol. Chem. 1999, 274, 6718-6725 10.1074/jbc.274.10.6718
49. Zebisch, K.; Voigt, V.; Wabitsch, M.; Brandsch, M. Protocol for Effective Differentiation of 3T3-L1 Cells to Adipocytes Anal. Biochem. 2012, 425, 88-90 10.1016/j.ab.2012.03.005
50. Sisignano, M.; Park, C.-K.; Angioni, C.; Zhang, D. D.; von Hehn, C.; Cobos, E. J.; Ghasemlou, N.; Xu, Z.-Z.; Kumaran, V.; Lu, R.; Grant, A.; Fischer, M. J. M.; Schmidtko, A.; Reeh, P.; Ji, R.-R.; Woolf, C. J.; Geisslinger, G.; Scholich, K.; Brenneis, C. 5,6-EET Is Released upon Neuronal Activity and Induces Mechanical Pain Hypersensitivity via TRPA1 on Central Afferent Terminals J. Neurosci. 2012, 32, 6364-6372 10.1523/JNEUROSCI.5793-11.2012